文献速递甲状腺与浅表USCT

超声引导下射频消融治疗低风险甲状腺微小乳头状癌:大规模人群的疗效与安全性

US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population.
PubMed 文献 · Korean J Radiol · 2019-01-01

本研究纳入2008年5月至2017年1月间133例患者的152个活检证实的低风险甲状腺微小乳头状癌,均因手术高风险或拒绝手术接受射频消融。随访至少6个月(平均39个月)显示,91.4%(139/152)的肿瘤完全消失,未完全消失的13个肿瘤均无残留病灶再生长;无局部复发、淋巴结或远处转移及新发甲状腺癌,无患者转手术;总并发症率3%(4/133),无危及生命的并发症或手术相关死亡。结论提示射频消融是手术高风险或拒绝手术的低风险甲状腺微小乳头状癌患者的有效且安全选择。

要点

  • 低风险甲状腺微小乳头状癌射频消融后完全消失率达91.4%(139/152),未完全消失者无再生长。
  • 随访期间无局部复发、淋巴结或远处转移,无新发甲状腺癌,无患者转手术。
  • 总并发症率3%(4/133),包括1例声音改变,无危及生命并发症或手术相关死亡。

核心结论

  • 结果表明,射频消融是手术高风险或拒绝手术的低风险甲状腺微小乳头状癌患者的有效且安全选择。

研究设计与样本

  • 研究纳入2008年5月至2017年1月间133例患者的152个活检证实的甲状腺微小乳头状癌,均因手术高风险或拒绝手术接受射频消融。
  • 治疗前采用超声和计算机断层扫描评估肿瘤及颈部转移情况,射频消融使用内部冷却甲状腺专用电极系统。
  • 随访至少6个月,初次射频消融后1周、2、6、12个月及之后每6-12个月行超声随访,评估消融肿瘤系列变化、新发癌、淋巴结或远处转移及并发症。

关键影像表现/征象

  • 91.4%(139/152)的消融肿瘤完全消失。
  • 13个未完全消失的肿瘤中,随访期间残留消融病灶均无再生长。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population.

MATERIALS AND METHODS: Cases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patients were either of high surgical risk or refused to undergo surgery. They were followed up for at least 6 months after initial RFA. Ultrasonography (US) and computed tomography were performed to evaluate the PTMC and the presence of neck metastasis before treatment. RFA was conducted using an internally cooled thyroid-dedicated electrode system. Follow-up US was performed at 1 week, and 2, 6, and 12 months, after the initial RFA, and then at every 6-12 months. We evaluated serial changes of ablated tumors, newly developed cancers, lymph node (LN) or distant metastasis and complications.

RESULTS: Complete disappearance was found in 91.4% (139/152) of ablated tumors. Among the 13 tumors in patients who did not show complete disappearance, no tumor displayed any regrowth of the residual ablated lesion during the follow-up period. The mean follow-up period was 39 months. During the follow-up period, there were no local recurrence, no LN or distant metastasis, and no newly developed thyroid cancers. No patients were referred to surgery. The overall complication rate was 3% (4/133) of patients, including one voice change. There were no life-threatening complications or procedure-related deaths.

CONCLUSION: Our results suggest that RFA is an effective and safe option for treating low-risk PTMC patients who are of high surgical risk or refuse surgery.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Lim HK, Cho SJ, Baek JH, et al. US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population. Korean J Radiol. 2019. PMID: 31854153. doi:10.3348/kjr.2019.0192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。